580 related articles for article (PubMed ID: 30094742)
1. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Zhao S; Chadwick L; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
Lu X; Hu R; Peng L; Liu M; Sun Z
Front Immunol; 2021; 12():638444. PubMed ID: 33889152
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.
Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F
Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302
[TBL] [Abstract][Full Text] [Related]
5. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.
Mengato D; Messori A
Clin Exp Rheumatol; 2018; 36(6):1118. PubMed ID: 29600941
[No Abstract] [Full Text] [Related]
7. SB5: An Adalimumab Biosimilar.
Frampton JE
BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
[TBL] [Abstract][Full Text] [Related]
8. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
Chadwick L; Zhao S; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H; Georgiadis S; Loft AG; Hendricks O; Jensen DV; Andersen M; Chrysidis S; Colic A; Danebod K; Hussein MR; Kalisz MH; Kristensen S; Lomborg N; Manilo N; Munk HL; Pedersen JK; Raun JL; Mehnert F; Krogh NS; Hetland ML; Glintborg B
Ann Rheum Dis; 2021 Nov; 80(11):1400-1409. PubMed ID: 33926921
[TBL] [Abstract][Full Text] [Related]
10. FKB327: An Adalimumab Biosimilar.
Al-Salama ZT
BioDrugs; 2019 Feb; 33(1):113-116. PubMed ID: 30712241
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P
Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
Jani RH; Gupta R; Bhatia G; Rathi G; Ashok Kumar P; Sharma R; Kumar U; Gauri LA; Jadhav P; Bartakke G; Haridas V; Jain D; Mendiratta SK
Int J Rheum Dis; 2016 Nov; 19(11):1157-1168. PubMed ID: 26176644
[TBL] [Abstract][Full Text] [Related]
14. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
[TBL] [Abstract][Full Text] [Related]
15. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
Cohen S; Pablos JL; Pavelka K; Müller GA; Matsumoto A; Kivitz A; Wang H; Krishnan E
Arthritis Res Ther; 2019 Mar; 21(1):84. PubMed ID: 30922373
[TBL] [Abstract][Full Text] [Related]
16. ABP 501 for the treatment of rheumatoid arthritis.
Pelechas E; Voulgari PV; Drosos AA
Expert Opin Biol Ther; 2018 Mar; 18(3):317-322. PubMed ID: 29350566
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of ZRC3197 (Adalimumab Biosimilar) in Patients with Inflammatory Arthritis: A Real-life Experience.
Sharma B
J Assoc Physicians India; 2017 May; 65(5 Suppl):22-25. PubMed ID: 28836747
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.
Bruni C; Bitti R; Nacci F; Cometi L; Tofani L; Bartoli F; Fiori G; Matucci-Cerinic M
Clin Rheumatol; 2021 Jan; 40(1):85-91. PubMed ID: 32514676
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
[No Abstract] [Full Text] [Related]
20. Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.
Cohen SB; Alonso-Ruiz A; Klimiuk PA; Lee EC; Peter N; Sonderegger I; Assudani D
Ann Rheum Dis; 2018 Jun; 77(6):914-921. PubMed ID: 29514803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
